InvisiMask™ Nasal Spray

The InvisiMask nasal spray is an investigational daily human antibody nasal spray designed to neutralize SARS-CoV-2, the virus that causes COVID-19, from airborne droplets and particles in the nasal cavity, the primary entry point of SARS-CoV-2 infection.

At the lowest dose of 25μg, the antibodies provided at least 10 hours of protection against infection in mice exposed to the highest viral load tested (107 virus particles administered intra-nasally).

Potential of the InvisiMask nasal spray

We envision the InvisiMask nasal spray to be used daily to provide an important line of personal protection against SARS-CoV-2 infection.
 

How does the InvisiMask nasal spray work?

Antibodies administered by InvisiMask nasal spray

Antibodies adhere to the upper respiratory tract

Antibodies neutralize the SARS-CoV-2 virus

The Eureka antibodies function by binding to the S1 spike protein of SARS-CoV-2 and preventing the virus from binding to the ACE2 receptor on cells in the upper respiratory system. This blocks SARS-CoV-2 from entering cells and triggering an infection.

Key attributes and advantages of the InvisiMask nasal spray

Key Attributes Advantages

Nasal spray format

  • Low cost and ease for personal administration

  • Provides at least 10 hours of protection in mice exposed to the highest viral load tested

  • Use as an additional means of protection against infection, for high risk individuals, and in situations in which face mask wearing is impractical

  • Storage at room temperature with long shelf life in comparison to vaccines (sub-zero storage) will simplify distribution and expand access

  • Complement to vaccines, therapeutics and other preventive measures such as face masks in slowing spread of COVID-19

Anti-SARS-CoV-2 human IgG antibodies

  • Anti-SARS-CoV-2 antibody treatments have already been approved by the FDA for confirmed cases of COVID-19

  • Antibodies provide active protection in neutralizing the SARS-CoV-2 virus

  • IgG antibody manufacturing process is well-established and versatile for large scale production

  • Eureka’s InvisiMask antibodies have been tested against more than 20 SARS-CoV-2 variants reported in COVID-19 patients, including the highly infectious D614G mutant

  • Human antibody reduces risk of immune response to nasal spray made with foreign peptides or non-human originated antibodies

High Affinity and Specificity Antibodies

  • Provides potent neutralization of SARS-CoV-2 virus at low doses

  • Low risk of cross-reactivity with non-spike protein targets

Proprietary Adhesion Technology

  • Increases the retention time of the antibody on respiratory mucosal surfaces and extends the duration of protection against infection

Paper

Intranasal administration of SARS-CoV-2 neutralizing human antibody prevents infection in mice, see data posted on bioRxiv

FAQ

Frequently Asked Questions about the InvisiMask

Current Status

Eureka is preparing an Investigational New Drug (IND) application with the FDA to conduct a clinical trial of the InvisiMask nasal spray.

Inquiries

For inquiries, e-mail: invisimask@eurekaninc.com